The Impact of Cannabidiol (CBD) Health Claims at Point-of-Sale on Consumer Perceptions and Behavior

销售点大麻二酚 (CBD) 健康声明对消费者认知和行为的影响

• 批准号: 10620707
• 负责人: Kimberly G. Wagoner
• 金额: $ 56.33万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10620707
• 关键词: Address; Adult; Advertising; Age; Agriculture; Alzheimer' s Disease; Authorization documentation; Behavior; Benefits and Risks; Beverages; Cannabidiol; Cannabis; Cannabis policy; Cannabis sativa plant; Categories; Chemicals; Classification; Confusion; Cosmetics; Coupled; Development; Discipline; Drug Interactions; Drug Prescriptions; Drug abuse; Ensure; Environment; Epidiolex; Epilepsy; Expectancy; Explosion; Food; Food Additives; Future; Health; Hemp; Hepatotoxicity; Imaging technology; Industry; Intoxication; Laws; Letters; Mainstreaming; Malignant Neoplasms; Marijuana; Marketing; Medical; Methods; Nutritional; Online Systems; Outcome; Participant; Perception; Pharmaceutical Preparations; Photography; Policies; Policy Research; Predisposition; Prevalence; Psychotropic Drugs; Public Health; Randomized, Controlled Trials; Regulation; Report (document); Reporting; Research; Research Personnel; Research Priority; Risk; Safety; Sales; Sampling; Schedule; Science; Structure; Supervision; Surveys; Syndrome; Testing; Tetrahydrocannabinol; Therapeutic; Tobacco; Uncertainty; United States Food and Drug Administration; arm; authority; chronic pain; chronic pain relief; consumer behavior; dietary supplements; health communication; high risk; improved; innovation; interest; marijuana use; medical specialties; prevent; tobacco regulatory science; vaping; willingness

Project Summary Cannabidiol (CBD) products have rapidly gained popularity, with more than 46 million US adults reporting use, primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as having therapeutic benefits, be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been unlawfully advertised online to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer, preventing Alzheimer’s disease and providing chronic pain relief. This a public health concern as these claims may reduce perceptions of harm, increase perceived benefits and influence consumers to delay medical treatment. Coupled with lacking scientific evidence on CBD’s safety and efficacy and uncertainty about product quality, consumers are at risk for unintended consequences including liver toxicity and adverse drug interactions with existing medications if they are misled about CBD’s risks and benefits by illicit health claims. This project, focused on informing regulatory actions for CBD, aims to document the types of health claims being made by brick and mortar CBD retailers, evaluate consumer perceptions of them, and assess their impact on consumer purchase of CBD. First, we will document health claims displayed in a large sample of CBD retailers from three states with contrasting cannabis policies. Our team and experts in cannabis, public health regulation and health communication will content analyze the health claims to identify potential FDA-prohibited claims. Next, we will assess consumer perceptions of the real-world CBD health claims by conducting a web-based survey with a nationally representative sample of 3,000 adult CBD users and non-users. Participants will assess if the claims indicate a FDA-prohibited category, share their interpreted meaning of each claim, and interest in trying CBD. Finally, in Aim 3, we will examine the impact of CBD health claims on consumer purchase behavior using a simulated retail environment. We will conduct a two-arm (CBD claims, no claim control) randomized controlled trial (RCT) in a simulated CBD retailer with 400 adult CBD users and susceptible non-users to evaluate the impact of CBD health claims on the purchase of CBD products (primary), willingness to try, perceived benefits, product safety, and outcome expectancies. The proposed study, informed by multiple disciplines including tobacco regulatory science and food and nutritional claims, will be the first to document health claims made by CBD retailers, assess consumer perceptions of those claims, and test the impact of claims on consumer behavior in a real-world RCT. This study will directly inform regulatory actions, assisting FDA in determining which claims consumers interpret in ways prohibited by law and ensuring consumers are not misled about CBD.

项目摘要 大麻二醇(CBD)产品迅速流行，超过4600万美国成年人报告使用， 主要用于治疗医学疾病。不断增长的CBD市场涵盖了美国食品 美国食品和药物管理局(FDA)对药品、膳食补充剂、食品/饮料和化妆品进行了监管。 CBD不能被宣传为具有治疗益处，不能向消费者虚假或误导，也不能传达 产品由FDA批准或认可。此外，CBD不能作为食品添加剂或 膳食补充剂，因为它是一种被批准的药物Epidiolex的有效成分。尽管如此，CBD产品 在网上非法向消费者宣传这些声明，包括未经证实的健康声明 这促进了包括治愈癌症、预防阿尔茨海默病和缓解慢性疼痛在内的好处。 这是一个公共卫生问题，因为这些声明可能会减少人们对伤害的感知，增加感知到的好处，并 影响消费者延误就医。再加上缺乏关于CBD安全性的科学证据 有效性和产品质量的不确定性，消费者面临着意外后果的风险，包括 肝脏毒性和与现有药物的不良药物相互作用如果误导了CBD的风险和 非法健康声明带来的好处。该项目的重点是为CBD的监管行动提供信息，旨在 记录实体CBD零售商提出的健康声明的类型，评估消费者 对他们的看法，并评估他们对消费者购买CBD的影响。首先，我们将记录健康 来自三个州的CBD零售商的大样本中显示了大麻政策的反差。我们的 大麻、公共卫生监管和健康传播方面的团队和专家将分析内容 健康声明，以确定潜在的FDA禁止的声明。接下来，我们将评估消费者对 通过对具有全国代表性的以下人群进行基于网络的调查，对真实世界的CBD健康声明进行调查 3,000名成年CBD用户和非用户。参与者将评估这些声明是否表明FDA禁止的类别， 分享他们对每个主张的解释含义，以及对尝试CBD的兴趣。最后，在目标3中，我们将研究 模拟零售环境下CBD健康声明对消费者购买行为的影响。我们会 在模拟的CBD中进行双臂(CBD索赔，无索赔控制)随机对照试验(RCT) 一家有400名成年CBD用户和易受影响的非用户的零售商，评估CBD健康声明对 购买CBD产品(主要)、尝试的意愿、感知的好处、产品安全性和结果 期望值。这项拟议的研究由多个学科提供信息，包括烟草监管科学和 食品和营养声明，将第一个记录CBD零售商的健康声明，评估消费者 这些主张的认知，并在现实世界的RCT中测试索赔对消费者行为的影响。这 研究将直接向监管行动提供信息，帮助FDA确定消费者在 法律禁止的方式，确保消费者在CBD上不被误导。

项目成果

Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.

• DOI: 10.3389/fpubh.2022.893009
• 发表时间: 2022
• 期刊: FRONTIERS IN PUBLIC HEALTH
• 影响因子: 5.2
• 作者: Dobbins, MaryBeth;Rakkar, Mannat;Cunnane, Katharine;Pennypacker, Sarah D.;Wagoner, Kimberly G.;Reboussin, Beth A.;Romero-Sandoval, E. Alfonso
• 通讯作者: Romero-Sandoval, E. Alfonso